SPY442.06-3.69 -0.83%
DIA345.39-2.05 -0.59%
IXIC15,026.21-155.71 -1.03%

BRIEF-Janssen Gets FDA Approval For Schizophrenia Treatment Invega Hafyera

reuters.com · 09/01/2021 08:04
BRIEF-Janssen Gets FDA Approval For Schizophrenia Treatment Invega Hafyera

- Johnson & Johnson JNJ:

  • JANSSEN ANNOUNCES U.S. FDA APPROVAL OF INVEGA HAFYERA™ (6-MONTH PALIPERIDONE PALMITATE), FIRST AND ONLY TWICE-YEARLY TREATMENT FOR ADULTS WITH SCHIZOPHRENIA

  • JANSSEN - PHASE 3 NON-INFERIORITY STUDY RESULTS SHOWED OVER 92% OF PARTICIPANTS WERE RELAPSE-FREE AT 12 MONTHS

Source text for Eikon: ID:nPnbLKB6a

Further company coverage: JNJ


((Reuters.Briefs@thomsonreuters.com;))